Current Problems in Cancer
Volume 31, Issue 3 , Pages 226-236 , May 2007

Epidemiology of Prostate Cancer in Africa: Another Step in the Understanding of the Disease?

References 

  1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–1427
  2. Gueye SM, Zeigler-Johnson CM, Friebel T, et al. Clinical characteristics of prostate cancer in African Americans, Americans whites, and Senegalese men. Urology. 2003;61:987–992
  3. Echimane AK, Ahnoux AA, Aboubi I, et al. Cancer incidence in Abidjan, Ivory Coast (First results from the Cancer Registry, 1995-1997). Cancer. 2000;89:653–663
  4. Glover FE, Coffey DS, Douglas LL, et al. The epidemiology of prostate cancer in Jamaica. J Urol. 1998;159:1984–1986
  5. Ravery V, Javerliat I, Toublanc M, et al. Features of prostatic cancer in French individuals of African-Caribbean origin. Prog Urol. 2000;10:231–236
  6. Antopoulos IM, Pompeo ACL, El Hayek OR, et al. Results of prostate cancer screening in non symptomatic men. Braz J Urol. 2001;27:227–234
  7. Brawley OW. Prostate cancer and black men. Semin Urol Oncol. 1998;16:184–186
  8. Littrup PJ. Editorial: Prostate cancer in African-American men. Prostate. 1997;31:139
  9. Austin JP, Aziz H, Potters L, et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol. 1990;121:761–762
  10. Fowler JE, Bigler SA, Bowman G, Kilambi NK. Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment. J Urol. 2000;163:137–142
  11. Pienta KJ, Demers R, Hoff M, et al. Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tricounty area: 1973 to 1987. Urology. 1995;45:93–102
  12. Powell IJ, Schwartz K, Hussain M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? (A comparative study between black and white men in a Veteran affairs system). Urology. 1995;46:825–830
  13. Powell IJ, Heilbrun L, Littrup P, et al. Outcome of African American men screened for prostate cancer, the DEED (Detroit Education and Early Detection) study. J Urol. 1997;158:146–149
  14. Tewari A, Horninger W, Pelzer AE, et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int. 2005;96:1247–1252
  15. Ellis L, Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids. 1992;57:72–75
  16. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer?. (Hypothesis) Anticancer Res. 1990;10:1307–1312
  17. Buttyan RS, Sawczuk IS, Benson MC, et al. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate. 1987;11:327–337
  18. Mettlin C, Selenkas S, Natarajan N, Huben R. Betacarotene and animal fats and their relationship to prostate cancer risk. Cancer. 1989;64:605–612
  19. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiological and clinical features. J Urol. 1993;150:797–802
  20. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996;274:1371–1374
  21. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004;13:103–121
  22. Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate cancer in southern Sweden (A population-based case-control study). Eur J Cancer. 1999;35:272–277
  23. Ukoli F, Osime U, Akereyeni F, et al. Prevalence of elevated serum prostate-specific antigen in rural Nigeria. Int J Urol. 2003;10:315–322
  24. Bah E, Hall AJ, Inskip HM. The first 2 years of the Gambian National Cancer Registry. Br J Cancer. 1990;62:647–650
  25. Bayo S, Parkin DM, Koumare AK, et al. Cancer in Mali, 1987-1988. Int J Cancer. 1990;45:679–684
  26. Koulibali M, Kabba IS, Cisse A, et al. Cancer incidence in Konakry, Guinea (First results from the Cancer Registry 1992-1995). Int J Cancer. 1997;70:39–45
  27. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, vol VII. IARC scientific publication no. 143. Lyon, France: International Agency for Research on Cancer; 1997;
  28. Chokunonga E, Levy LM, Bassett MT, et al. Cancer incidence in the African population of Harare, Zimbabwe: second results from the Cancer Registry 1993-1995. Int J Cancer. 2000;85:54–59
  29. Wabinga HR, Parkin DM, Wabwire Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda 1960-1997. Br J Cancer. 2000;82:1585–1592
  30. Osegbe DN. Prostate cancer in Nigerians: facts and nonfacts. J Urol. 1997;157:1340–1343
  31. Yatani R, Shiraishi T, Nakakuki K, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst. 1988;80:683–687
  32. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8:439–444
  33. Guileyardo JM, Johnson WD, Welsh RA, et al. Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst. 1980;65:311–316
  34. Denton SE, Choy SH, Valk WL. Occult prostate carcinoma diagnosed by the step-section technique of surgical specimen. J Urol. 1965;93:296–298
  35. Montie JE, Wood DP, Pontes JE, Boyett JM, Levin HS. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer. 1989;63:381–385
  36. Abbas F, Hochberg D, Civantos F, Soloway M. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol. 1996;30:322–326
  37. Singh A, Kinoshita Y, Rovito PM, et al. Higher than expected association of clinical prostate and bladder cancers. J Urol. 2005;173:1526–1529
  38. Akazaki K, Stemmermann GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst. 1973;50:1137–1144
  39. Sanchez-Chapado M, Olmedilla G, Cabeza M, et al. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003;54:238–247
  40. Breslow N, Chan CW, Dhom G, et al. The International Agency for Research on Cancer, Lyons, France Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer. 1977;20:680–688
  41. Koug XT, Xia TL, Gu FL. Study of the latent carcinoma of prostate in China. BJU. 1997;80:A895
  42. Stamatiou K, Alevizos A, Perimeni D, et al. Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study. Prostate Cancer Prostatic Dis. 2006;9:45–49
  43. Soos G, Tsakiris I, Szanto J, et al. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol. 2005;48:739–744
  44. Stemmermann GN, Nomura AMY, Chyou PH, Yatani R. A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience. Cancer Epidemiol Biomarkers Prev. 1992;1:189–193
  45. Jackson MA, Kovi J, Heshmat TA, et al. Characterization of prostatic carcinoma among blacks: a comparison between a low-incidence area, Ibadan, Nigeria, and a high-incidence area, Washington, DC. Prostate. 1980;1:185–205
  46. Dezso B, Soos G, Tsakiris I, Haas GP. Re: Differences of prostate cancer incidence on autopsy material between European Caucasian male populations (in response to Stamatiou KN, et al: Reply to Soos G, et al. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol 2005;48(5):739-44). Eur Urol. 2006;49(6):1139–1140
  47. International Agency for Research on Cancer: Incidence of prostate cancer in Africa. Available from: http://www-dep.iarc.fr.

PII: S0147-0272(07)00005-0

doi: 10.1016/j.currproblcancer.2007.01.004

Current Problems in Cancer
Volume 31, Issue 3 , Pages 226-236 , May 2007

Article Tools

* Image Usage & Resolution